Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 4152

1.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
2.
3.

VEGF receptor signaling in tumor angiogenesis.

McMahon G.

Oncologist. 2000;5 Suppl 1:3-10. Review.

4.

Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.

Shibuya M.

J Biochem Mol Biol. 2006 Sep 30;39(5):469-78. Review.

PMID:
17002866
5.

[Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway].

Wang F, Tian YH, Li L, Chen XF, Hu HH, Li CY, Huang Q.

Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002 Mar;34(2):165-70. Chinese.

PMID:
12006990
6.

Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.

Ellis LM, Takahashi Y, Liu W, Shaheen RM.

Oncologist. 2000;5 Suppl 1:11-5.

7.

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.

Cancer Res. 2000 Apr 15;60(8):2178-89.

8.

KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.

Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Nakatani T, Tsujinoue H, Fukui H.

Hepatology. 1999 Nov;30(5):1179-86.

PMID:
10534339
9.

Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.

Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF.

EXS. 1997;79:233-69. Review.

PMID:
9002222
11.
12.

Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE.

Cancer Res. 2000 Sep 15;60(18):5117-24.

13.

Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors.

Kojima-Yuasa A, Hua JJ, Kennedy DO, Matsui-Yuasa I.

Life Sci. 2003 Jul 25;73(10):1299-313.

PMID:
12850245
14.
15.
16.

A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.

Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Büttner M, Rziha HJ, Dehio C.

EMBO J. 1999 Jan 15;18(2):363-74.

17.

Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.

Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G.

Cancer Res. 2003 Jun 15;63(12):3403-12.

18.

Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.

Jia H, Jezequel S, Löhr M, Shaikh S, Davis D, Soker S, Selwood D, Zachary I.

Biochem Biophys Res Commun. 2001 Apr 27;283(1):164-73.

PMID:
11322784
19.

VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.

Fine BA, Valente PT, Feinstein GI, Dey T.

Gynecol Oncol. 2000 Jan;76(1):33-9.

PMID:
10620438
20.

Vascular endothelial growth factor (VEGF) inhibition--a critical review.

Moreira IS, Fernandes PA, Ramos MJ.

Anticancer Agents Med Chem. 2007 Mar;7(2):223-45. Review.

PMID:
17348829

Supplemental Content

Support Center